Innovis Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Innovis Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$982K	Sell	1,193 -435	-27%	-$342K	0.38%	46
2023 Q2	$1.17M	Sell	1,628 -15	-0.9%	-$11.6K	0.43%	43
2023 Q1	$1.35M	Buy	1,643 +11	+0.7%	+$8.3K	0.55%	41
2022 Q4	$1.18M	Buy	+1,632	New	+$1.2M	0.53%	38

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Innovis Asset Management's REGN Position: Q3 2023 in Review

Innovis Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 27% in Q3 2023, selling an estimated $342K and leaving 1,193 shares worth $982K. The position accounts for 0.38% of the portfolio, ranked #46.

Innovis Asset Management first reported a position in REGN in Q4 2022 and has held it in 4 quarters since. The position peaked at $1.35M in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Innovis Asset Management held 1,193 shares of Regeneron Pharmaceuticals worth $982K as of Q3 2023.
Innovis Asset Management sold 435 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $342K.
Regeneron Pharmaceuticals made up 0.38% of Innovis Asset Management's portfolio in Q3 2023, its #46 holding.
Innovis Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
Innovis Asset Management's Regeneron Pharmaceuticals position peaked at $1.35M in Q1 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.